We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Read MoreHide Full Article
Key Takeaways
Haemonetics shares surged 149.3% in a year, defying the industry's 26.8% decline amid MedSurg growth.
HAE's MedSurg revenues rose 6% to $148.1 million in fiscal Q1 2027, aided by Blood Management growth.
HAE's NexSys PCS upgrades support growth, but competition and unfavorable currency trends pose risks.
Haemonetics Corporation’s (HAE - Free Report) impressive MedSurg business is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, fierce competitive pressure and unfavorable foreign exchange remain concerns for HAE’s operations.
In the past year, this Zacks Rank #3 (Hold) company’s shares have gained 149.3% against the industry’s decline of 26.8%. The S&P 500 composite has grown 18% in the same time frame.
The global provider of blood and plasma supplies and services has a market capitalization of $2.82 billion. HAE beat on earnings in each of the trailing four quarters, delivering an average surprise of 5.97%.
Let us delve deeper.
Haemonetics’ Key Upsides
MedSurg Growth Broadens: Haemonetics’ MedSurg business is supported by Blood Management Technologies and Interventional Technologies, giving the company multiple avenues for growth. Recent acquisitions expanded the portfolio through Vivasure Medical, Attune Medical and OpSens, adding vascular closure, esophageal protection and sensor-guided technologies.
In the first quarter of fiscal 2027, MedSurg revenues increased 6.0% on a reported basis and 5.9% organically to $148.1 million. Blood Management Technologies grew 8.1% organically, with double-digit growth in Hemostasis and Transfusion Management partly offset by slower Cell Salvage capital upgrades. Transfusion Management continued to benefit from software implementations and faster customer activations, expanding the recurring revenue base.
Interventional Technologies returned to growth, increasing 2.8% organically as Vascular Closure grew in the low double digits. VASCADE MVP and MVP XL benefited from renewed U.S. momentum, broader utilization and the expanded MVP XL indication for sheaths up to 17F outer diameter.
NexSys PCS Platform Continues to Advance: Haemonetics’ FDA-cleared NexSys PCS plasma collection system is designed to increase plasma yield, improve center productivity, enhance the donor experience and support safe, reliable collections. The bi-directionally connected NexSys PCS with NexLynk DMS has historically reduced donor door-to-door time by an average of 16 minutes.
Persona Technology further strengthens the platform’s value proposition. Persona PLUS, the latest firmware-based enhancement, is delivering yield improvements above 5% versus earlier Persona offerings and can be deployed without replacing devices. Adoption accelerated in the first quarter of fiscal 2027 and is progressing ahead of schedule. Continued upgrades can deepen customer integration and support higher-value recurring disposable revenues.
Image Source: Zacks Investment Research
What Ails HAE Stock?
Competitive Risks Remain: Haemonetics operates in a competitive environment, both for manual and automated systems. Slower-than-expected product adoption by customers, especially the American Red Cross, might reduce the company’s revenues and profit.
Foreign Exchange Can Affect Earnings: Haemonetics generates a meaningful share of sales outside the United States and conducts international business in local currencies, including the Japanese yen, euro and Chinese yuan. In the first quarter of fiscal 2027, management said earnings growth was achieved despite unfavorable foreign exchange. Full-year fiscal 2027 guidance assumes a 0-1% currency impact to reported revenues. Currency movements can therefore continue to create volatility in translated sales and earnings.
HAE’s Estimate Trend
The Zacks Consensus Estimate for fiscal 2026 earnings has remained unchanged at $5.29 per share in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.41 billion, which indicates a 5.9% increase from the year-ago reported number.
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7% yield. Shares of the company have increased 2.6% against the industry’s 27.9% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
Abbott, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 22.5% compared with the industry’s 27.9% decline over the past year.
Globus Medical, currently carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.6% compared with the industry’s 7.3% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Key Takeaways
Haemonetics Corporation’s (HAE - Free Report) impressive MedSurg business is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, fierce competitive pressure and unfavorable foreign exchange remain concerns for HAE’s operations.
In the past year, this Zacks Rank #3 (Hold) company’s shares have gained 149.3% against the industry’s decline of 26.8%. The S&P 500 composite has grown 18% in the same time frame.
The global provider of blood and plasma supplies and services has a market capitalization of $2.82 billion. HAE beat on earnings in each of the trailing four quarters, delivering an average surprise of 5.97%.
Let us delve deeper.
Haemonetics’ Key Upsides
MedSurg Growth Broadens: Haemonetics’ MedSurg business is supported by Blood Management Technologies and Interventional Technologies, giving the company multiple avenues for growth. Recent acquisitions expanded the portfolio through Vivasure Medical, Attune Medical and OpSens, adding vascular closure, esophageal protection and sensor-guided technologies.
In the first quarter of fiscal 2027, MedSurg revenues increased 6.0% on a reported basis and 5.9% organically to $148.1 million. Blood Management Technologies grew 8.1% organically, with double-digit growth in Hemostasis and Transfusion Management partly offset by slower Cell Salvage capital upgrades. Transfusion Management continued to benefit from software implementations and faster customer activations, expanding the recurring revenue base.
Interventional Technologies returned to growth, increasing 2.8% organically as Vascular Closure grew in the low double digits. VASCADE MVP and MVP XL benefited from renewed U.S. momentum, broader utilization and the expanded MVP XL indication for sheaths up to 17F outer diameter.
NexSys PCS Platform Continues to Advance: Haemonetics’ FDA-cleared NexSys PCS plasma collection system is designed to increase plasma yield, improve center productivity, enhance the donor experience and support safe, reliable collections. The bi-directionally connected NexSys PCS with NexLynk DMS has historically reduced donor door-to-door time by an average of 16 minutes.
Persona Technology further strengthens the platform’s value proposition. Persona PLUS, the latest firmware-based enhancement, is delivering yield improvements above 5% versus earlier Persona offerings and can be deployed without replacing devices. Adoption accelerated in the first quarter of fiscal 2027 and is progressing ahead of schedule. Continued upgrades can deepen customer integration and support higher-value recurring disposable revenues.
Image Source: Zacks Investment Research
What Ails HAE Stock?
Competitive Risks Remain: Haemonetics operates in a competitive environment, both for manual and automated systems. Slower-than-expected product adoption by customers, especially the American Red Cross, might reduce the company’s revenues and profit.
Foreign Exchange Can Affect Earnings: Haemonetics generates a meaningful share of sales outside the United States and conducts international business in local currencies, including the Japanese yen, euro and Chinese yuan. In the first quarter of fiscal 2027, management said earnings growth was achieved despite unfavorable foreign exchange. Full-year fiscal 2027 guidance assumes a 0-1% currency impact to reported revenues. Currency movements can therefore continue to create volatility in translated sales and earnings.
HAE’s Estimate Trend
The Zacks Consensus Estimate for fiscal 2026 earnings has remained unchanged at $5.29 per share in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.41 billion, which indicates a 5.9% increase from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7% yield. Shares of the company have increased 2.6% against the industry’s 27.9% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 22.5% compared with the industry’s 27.9% decline over the past year.
Globus Medical, currently carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.6% compared with the industry’s 7.3% growth over the past year.